Gross Profit
The latest quarterly gross profit is $529.10M with a quarterly period change of (6.95%). Gross profit is revenue minus cost of revenue, before operating expenses, interest, and taxes.
PODD Gross Profit
Reported quarterly gross profit; no daily interpolation.
PODD Quarterly Gross Profit Growth (YoY)
Gross Profit growth vs the same quarter one year earlier, last 20 quarters.
Gross Profit CAGR (Compound Annual Growth Rate)
1 Year
+33.08%
3 Year
+35.04%
5 Year
+27.03%
10 Year
+29.17%
15 Year
+28.33%
20 Year
+49.37%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
Quarterly Gross Profit History
| Period | Gross Profit | % Change |
|---|---|---|
| Q1 2026 | $529.10M | (6.95%) |
| Q4 2025 | $568.60M | +11.47% |
| Q3 2025 | $510.10M | +12.80% |
| Q2 2025 | $452.20M | +10.56% |
| Q1 2025 | $409.00M | (5.08%) |
| Q4 2024 | $430.90M | +14.27% |
| Q3 2024 | $377.10M | +13.96% |
| Q2 2024 | $330.90M | +7.86% |
| Q1 2024 | $306.80M | (15.06%) |
| Q4 2023 | $361.20M | +23.15% |
| Q3 2023 | $293.30M | +10.72% |
| Q2 2023 | $264.90M | +10.15% |
| Q1 2023 | $240.50M | +10.68% |
| Q4 2022 | $217.30M | +15.40% |
| Q3 2022 | $188.30M | (1.05%) |
| Q2 2022 | $190.30M | (9.25%) |
| Q1 2022 | $209.70M | (1.64%) |
| Q4 2021 | $213.20M | +12.98% |
| Q3 2021 | $188.70M | +3.28% |
| Q2 2021 | $182.70M | +9.07% |
| Q1 2021 | $167.50M | +3.97% |
| Q4 2020 | $161.10M | +6.13% |
| Q3 2020 | $151.80M | +6.53% |
| Q2 2020 | $142.50M | +12.29% |
| Q1 2020 | $126.90M | (5.37%) |
| Q4 2019 | $134.10M | +8.95% |
| Q3 2019 | $123.08M | +5.72% |
| Q2 2019 | $116.42M | +9.11% |
| Q1 2019 | $106.70M | (3.28%) |
| Q4 2018 | $110.31M | +8.18% |
| Q3 2018 | $101.97M | +24.24% |
| Q2 2018 | $82.07M | +8.25% |
| Q1 2018 | $75.81M | (4.64%) |
| Q4 2017 | $79.51M | +7.99% |
| Q3 2017 | $73.62M | +13.90% |
| Q2 2017 | $64.64M | +8.82% |
| Q1 2017 | $59.40M | (2.53%) |
| Q4 2016 | $60.94M | +9.52% |
| Q3 2016 | $55.64M | +10.27% |
| Q2 2016 | $50.46M | +14.54% |
| Q1 2016 | $44.05M | (2.80%) |
| Q4 2015 | $45.32M | +27.12% |
| Q3 2015 | $35.65M | +3.71% |
| Q2 2015 | $34.38M | +4.78% |
| Q1 2015 | $32.81M | (10.54%) |
| Q4 2014 | $36.67M | (3.60%) |
| Q3 2014 | $38.04M | +6.37% |
| Q2 2014 | $35.77M | +9.01% |
| Q1 2014 | $32.81M | (0.64%) |
| Q4 2013 | $33.02M | +20.53% |
| Q3 2013 | $27.39M | +2.09% |
| Q2 2013 | $26.83M | +6.67% |
| Q1 2013 | $25.16M | (0.65%) |
| Q4 2012 | $25.32M | +3.81% |
| Q3 2012 | $24.39M | +9.22% |
| Q2 2012 | $22.33M | +10.03% |
| Q1 2012 | $20.30M | +1.08% |
| Q4 2011 | $20.08M | +8.18% |
| Q3 2011 | $18.56M | +27.67% |
| Q2 2011 | $14.54M | +7.43% |
| Q1 2011 | $13.53M | (2.12%) |
| Q4 2010 | $13.83M | +18.89% |
| Q3 2010 | $11.63M | +17.63% |
| Q2 2010 | $9.89M | +17.90% |
| Q1 2010 | $8.38M | +14.33% |
| Q4 2009 | $7.33M | +26.47% |
| Q3 2009 | $5.80M | +82.99% |
| Q2 2009 | $3.17M | +58.85% |
| Q1 2009 | $2.00M | +66.53% |
| Q4 2008 | $1.20M | +1477.01% |
| Q3 2008 | ($87,000) | +96.33% |
| Q2 2008 | ($2.37M) | +28.82% |
| Q1 2008 | ($3.33M) | (43.53%) |
| Q4 2007 | ($2.32M) | +38.87% |
| Q3 2007 | ($3.79M) | (2.85%) |
| Q2 2007 | ($3.69M) | (43.80%) |
| Q1 2007 | ($2.56M) | (11.43%) |
| Q4 2006 | ($2.30M) | +28.81% |
| Q3 2006 | ($3.23M) | (579.53%) |
| Q2 2006 | $674,000 | +0.00% |
| Q1 2006 | $674,000 | - |
| Q4 2005 | $0 | - |
| Q3 2005 | $0 | - |
| Q2 2005 | $0 | - |
| Q1 2005 | $0 | - |
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy